Latest Headlines

Latest Headlines

Biogen Idec buys into Eisai's BACE camp on Alzheimer's as drug race heats up

The big biotech worked a deal with Eisai, offering to cover half of the research and development costs of a pair of mid-stage Alzheimer's therapies and adding an unspecified package of milestones and an upfront in exchange for half the potential profits. 

Eisai's revved-up Belviq marketing starting to pay off, analysts say

When it comes to addressing the market, pharma has three P's, according to Eisai's Michael O'Brien: physician, payer and patient. And as VP of specialty marketing, O'Brien is looking to hit each of them in promoting the recently launched weight-loss drug Belviq.

Eisai readies applications for thyroid cancer drug after PhIII success

Eisai has begun to lay the groundwork for a slate of marketing applications in the U.S., Europe and Japan for a new thyroid cancer therapy after wrapping up a successful Phase III study of the drug, which is also noteworthy for relying on an innovative collaborative approach to the development process

Eisai to cut R&D, even as it boosts its sales operation

Japanese drugmaker Eisai is cutting its R&D operations, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers around the world.

UPDATED: Eisai brings ax down on U.S. R&D op, chops 130 staffers worldwide

Eisai announced late last week that it is bringing the ax down on its R&D facility in Andover, MA, and other research centers around the globe as it chops 130 staffers out of its operations.

Eisai bets another $60M on Arena's Belviq with worldwide marketing deal

Eisai gave Arena Pharmaceuticals' obesity drug Belviq another vote of confidence. The Japanese drugmaker, already marketing the drug in the U.S., signed up to promote it in most other global markets, too. And it gave Arena a $60 million up-front payment to seal the deal.

Eisai slashes U.K. R&D jobs in 'global' restructuring

Japan's Eisai is slashing 20 R&D jobs and eliminating some 30 consultants contracts in the UK as part of a global R&D restructuring, according to a local spokesperson for the company. 

Japan's frustrated Eisai loses fight with DEA

Japan's Eisai, which lashed out this week at the U.K.'s cost watchdog as too restrictive, has lost its bid to force the DEA to schedule Fycompa so it can get it launched in the U.S. The seizure drug was approved by the FDA a year ago.

Japan's Eisai says U.K. cost watchdogs must open up--or else

Plenty of drugmakers have grumbled about the U.K.'s cost-effectiveness gatekeepers. The National Institute for Health and Care Excellence does routinely reject new drugs, particularly unless--and until--their makers offer price breaks. But until now, no major drugmaker has threatened to stop investing in Britain unless NICE changes its game.

Eisai to recruit 200 new sales reps for amped-up Belviq push

Analysts promised a battle of obesity drugs between Arena's Belviq and Vivus' Qsymia. But in marketing partner Eisai, Arena has a weapon Vivus lacks--and that weapon is about to get bigger. The Japanese company plans to add more than 200 sales reps to its army by December, doubling its size since the drug hit the market this June.